KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

Historic Current Deferred Revenue for GoodRx Holdings (GDRX) over the last 5 years, with Q1 2023 value amounting to $10.8 million.

  • GoodRx Holdings' Current Deferred Revenue rose 430.27% to $10.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $10.8 million, marking a year-over-year increase of 430.27%. This contributed to the annual value of $7.9 million for FY2022, which is 1500.95% up from last year.
  • As of Q1 2023, GoodRx Holdings' Current Deferred Revenue stood at $10.8 million, which was up 430.27% from $7.9 million recorded in Q4 2022.
  • In the past 5 years, GoodRx Holdings' Current Deferred Revenue ranged from a high of $11.5 million in Q2 2022 and a low of $3.5 million during Q4 2019
  • Its 5-year average for Current Deferred Revenue is $8.5 million, with a median of $8.5 million in 2021.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 9843.61% in 2020, then grew by 24.81% in 2021.
  • Quarter analysis of 5 years shows GoodRx Holdings' Current Deferred Revenue stood at $3.5 million in 2019, then skyrocketed by 98.44% to $6.9 million in 2020, then increased by 0.25% to $6.9 million in 2021, then increased by 15.01% to $7.9 million in 2022, then soared by 36.24% to $10.8 million in 2023.
  • Its Current Deferred Revenue stands at $10.8 million for Q1 2023, versus $7.9 million for Q4 2022 and $11.0 million for Q3 2022.